Loading
A phase 2 trial of Adebrelimab, Cetuximab and SHR-A2102 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.
A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour is a phase 2 interventional study registered as NCT06915142 by Shandong Suncadia Medicine Co., Ltd., with 300 participants planned, started 2025-04-28 and due to reach its primary completion in 2026-12. Interventions recorded: HRS-7058 + SHR-1316, HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy, HRS-7058 + Cetuximab, HRS-7058 + SHR-1826, HRS-7058 + SHR-1826 + SHR-1316 and HRS-7058 + SHR-A1202.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Cetuximab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/